Companies › Staidson (Beijing) Biopharmaceuticals
3 active drug programs in 4 registered trials: 2 Phase 3, 1 Phase 2, 1 Phase 1; Respiratory, Immunology, Genitourinary, Ophthalmology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BDB-001 injection | – | Phase 3 | ANCA Associated Vasculitis (AAV) | Apr 2027 |
| STSA-1002 injection | – | Phase 3 | Acute Respiratory Distress Syndrome (ARDS) | – |
| STSP-0902 ophthalmic solution Unclear - mechanism not stated in registry | – | Phase 2 | Neurotrophic Keratitis; Oligozoospermia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06975748 | STSP-0902 ophthalmic solution | Phase 2 | Neurotrophic Keratitis | Ophthalmology | Apr 2026 |
| NCT07208591 | STSA-1002 injection | Phase 3 | Acute Respiratory Distress Syndrome (ARDS) | Respiratory | Jul 2026 |
| NCT06948799 | STSP-0902 ophthalmic solution | Phase 1 | Oligozoospermia | Genitourinary | Jul 2026 |
| NCT07168161 | BDB-001 injection | Phase 3 | ANCA Associated Vasculitis (AAV) | Immunology | Apr 2027 |
No annotated target.
–
Priovant Therapeutics Sitala Bio Prana Therapies Enveda Therapeutics Lubris Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.